JLJuan Diego Martínez Lemus

Juan Diego Martínez Lemus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Diego Martínez Lemus has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stroke knowledge and intended care-seeking behavior among adults with hypertension and type 2 diabetes: A cross-sectional study

    by Luisa Fernanda Alviz, Juan Diego Oyola, Juan Diego Martinez-Lemus, Javier Alexander Perez-Lopez, Mariana Medina-Soler, Jaime Eduardo Rodriguez, John Benavides, Carlos Martinez, Claudio Jimenez

    Background: Stroke health literacy refers to the ability of non-medical individuals to recognize stroke symptoms and make timely decisions, which is critical for improving outcomes. However, data on stroke knowledge and intended care-seeking behavior in Bogotá, Colombia, remain limited. Objective: To assess stroke symptom knowledge and intended care-seeking behavior among adults with hypertension and type 2 diabetes and to identify sociodemographic predictors of limited knowledge and suboptimal response. Methods: A cross-sectional study was conducted between October 2023 and April 2024 in Bogotá, Colombia. A structured questionnaire was administered to 5,402 adults with hypertension and/or type 2 diabetes. Participants were recruited using a non-probabilistic sampling strategy, primarily from individuals under routine follow-up within the Bogotá public health network, and were identified through multiple recruitment strategies, including institutional databases. Surveys were conducted either by telephone or in person. Continuous variables were summarized using descriptive statistics, differences in categorical variables were assessed using chi-square tests, and binomial logistic regression models were applied to evaluate adjusted associations. Results: Of 6,050 respondents, 5,402 met inclusion criteria (median age 67 years; 46.3% male). Although most participants recognized that ischemic stroke can cause disability (89.6%) and death (91.1%), 32.5% reported no knowledge of stroke symptoms. Limited symptom knowledge was independently associated with male sex (OR 1.26, 95% CI 1.12–1.42), low educational attainment (OR 1.59, 95% CI 1.38–1.82), and low socioeconomic status (OR 2.20, 95% CI 1.85–2.60). Regarding intended response, 26.6% would not activate emergency medical services, and 52% reported they would schedule an outpatient appointment instead. Lower educational attainment was associated with greater likelihood of reporting non-emergency responses (all p < 0.001). Conclusions: Despite high awareness that stroke can cause disability and death, substantial gaps in symptom recognition and intended response persist, particularly among socioeconomically disadvantaged individuals. These findings highlight the need for targeted strategies to improve stroke literacy in high-risk populations.

  • NeuroMoE++: Patient-Adaptive Multi-Level Multimodal Fusion With Mixture-of-Experts for Neurological Disorder Classification

    by Wajih Hassan Raza, Yu Wen, Aamir Bader Shah, Yidan Shen, Juan Martinez-Lemus, Mya Caryn Schiess, Timothy Michael Ellmore, Renjie Hu, Xin Fu

    Early diagnosis of neurological disorders (NDs) benefits from multiple complementary signals, including anatomical MRI, diffusion imaging, functional activation, and clinical or serum biomarkers. These modalities capture distinct aspects of neurodegeneration and have motivated recent multimodal learning approaches. However, most existing methods combine modalities only at the feature or decision level through late fusion, meaning that modalities are processed independently and never influence one another during feature extraction. As a result, subtle cross-modality patterns that are highly informative in prodromal stages remain underutilized. To address this limitation, we propose NeuroMoE++, a hierarchical end-to-end framework that enables explicit interaction across modalities while preserving their individual structure. After obtaining unimodal and cross-modality predictions, a subject-driven adaptive integration produces patient-specific decisions. This combination allows the model to capture complementary structure, leverage fused evidence when beneficial, and remain interpretable from a clinical standpoint. Experiments on real clinical datasets demonstrate that NeuroMoE++ substantially outperforms unimodal and late-fusion baselines, achieving 84.94% accuracy. These results highlight the value of explicit cross-modality reasoning for practical neurological diagnosis.


  • Open Access

    Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial

    by Mya C. Schiess, Jessika Suescun, Juan D. Martinez‐Lemus, Charles Green, Tia S. Thomas, Mohammad Shahnawaz, Emily Tharp, Nikunj B. Satani, Jerome G. Saltarrelli, Christopher Adams, et al.

    Background: Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo‐hMSCs) may reduce neuroinflammation and improve motor symptoms. Objectives: To evaluate the efficacy of repeated intravenous doses of 10 × 10 6 /kg allo‐hMSCs in improving motor symptoms in patients with PD (PwP). Methods: In this phase 2, randomized, placebo‐controlled trial (November 2020–July 2023), mild‐to‐moderate PwP received either three allo‐hMSC infusions, one placebo followed by two allo‐hMSC infusions, or three placebo infusions at 18‐week intervals. Follow‐up lasted 88 weeks. The primary outcome was a >70% posterior probability (PP) of a difference in the proportion of participants with ≥5‐point improvement in OFF‐medication Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) at week 62. Bayesian analysis was conducted using R v4.2.0. Results: Forty‐five PwP were enrolled. A larger proportion of subjects achieved a ≥5‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with placebo at week 62 (mean difference [MD]: 5.0%, PP = 93.7%), translating to a 16.9‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with a 14.6‐point improvement in the placebo arm. Conversely, fewer subjects in the two‐infusion arm compared with placebo showed ≥5‐point improvement at week 62 (MD: –62.4%, PP ≥ 99.9%), translating to only a 3.9‐point improvement in MDS‐UPDRS‐III in the two‐infusion arm. However, improvement in MDS‐UPDRS‐III was seen across all treatment arms. Adverse events were mild and transient. Conclusions: Three infusions of 10 × 10 6 allo‐hMSCs/kg improved motor function in mild‐to‐moderate PwP, while two infusions showed less improvement than placebo. To address this discrepancy, future studies should conduct functional potency assays to understand batch‐to‐batch variability affecting clinical efficacy. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Tratamiento con toxina botulínica en un entorno de recursos limitados: experiencias de una institución pública

    by Gloria Andrea Panesso, Juan Diego Martínez, Annelise Velasco, Stefanía Forero, Daniel Perdomo, Ángela Villamil, Edna Rocío González, Claudio Alejandro Jiménez

    Introducción. La toxina botulínica se destaca por sus múltiples aplicaciones terapéuticas; tiene más de 30 indicaciones reconocidas en distintas especialidades. Sin embargo, a pesar de los estudios realizados en Latinoamérica, no hay una caracterización integral sobre su amplio espectro de uso clínico.Objetivo. Clasificar el uso farmacoterapéutico de la toxina botulínica en un centro de salud público de Bogotá, para identificar los riesgos de interacciones farmacológicas con otros compuestos y las posibles barreras para su uso. Se pretende fomentar una mejor comprensión de las indicaciones, prácticas y regulaciones de la toxina botulínica en el contexto colombiano.Materiales y métodos. Se realizó un estudio transversal en el que se analizó la administración de la toxina botulínica mediante la metodología de prescripción-indicación. Se recopiló información de las historias clínicas y del sistema de prescripción electrónica “Mi prescripción”. Para el análisis de los datos, se utilizó el software estadístico JAMOVI, versión 2.2.5.Resultados. De 197 pacientes tratados con la toxina botulínica, la mayoría de las prescripciones se registraron bajo la categoría de trastornos neurológicos (70,6 %), aunque la indicación más frecuente correspondió a alteraciones de la articulación temporomandibular (18,8 %). En niños, la indicación predominante fue la parálisis cerebral espástica (90 %). El 92,4 % de las aplicaciones clínicas coincidieron con las aprobadas por el Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia. Se identificaron riesgos de interacciones farmacológicas en el 30,9 % de los casos, asociadas significativamente con una carga anticolinérgica (p < 0,001).Conclusión. La toxina botulínica es ampliamente utilizada en Colombia debido a sus diversas indicaciones clínicas. En general, se encontró una buena correspondencia entre las prescripciones y las recomendaciones de las guías reguladoras. Es crucial evaluar los antecedentes farmacológicos de los pacientes para minimizar el riesgo de interacciones farmacológicas. Se subraya la necesidad de revisar y ajustar la normativa sobre el uso de la toxina botulínica en el país.


  • Open Access

    Role of alpha-synuclein seed amplification assay in Parkinson’s disease clinical trials: A case of misdiagnosis

    by Emily Tharp, Juan D. Martinez-Lemus, Mya C. Schiess, Timothy M. Ellmore, Jessika Suescun, Mohammad Shahnawaz


  • Open Access

    Costos médicos directos de los pacientes con ataque cerebrovascular isquémico en un hospital público de Bogotá, Colombia

    by Neiry María Zapa Pérez, Juan Diego Martínez Lemus, Alejandra Torres Ramírez, Claudio Alejandro Jiménez Monsalve

    Introducción: el ataque cerebrovascular isquémico (ACVi) es la segunda causa de muerte en Colombia. Se estimó que los costos asociados al ACVi podrían alcanzar los COP 5000 millones durante el 2019. Objetivo: describir los costos médicos directos de los pacientes que sufren de ACVi en una institución en Bogotá durante el 2020. Metodología: estudio de corte transversal que analiza los costos médicos directos de la atención hospitalaria de adultos que sufrieron un ACVi durante el 2020. Se compararon los costos, la estancia y los desenlaces clínicos de pacientes que recibieron trombólisis frente aquellos que no la recibieron. Resultados: los costos directos relacionados con 132 pacientes con ACVi fueron COP 1.218.970.831 en el año 2020 en nuestra institución. El costo promedio por paciente fue COP 7.845.073. Entre los eventos hospitalarios, las imágenes diagnósticas y otros métodos diagnósticos representaron la mayor proporción de costos (40?%), entre los que se destacó la angiotomografía de cabeza y cuello. La severidad del ACV influyó significativamente en los costos totales (p?=?0,018), así como en los costos de los medicamentos (p?<?0,001), procedimientos (p?<?0,001) y la estancia hospitalaria (p?<?0,029). Los pacientes sometidos a trombólisis resultaron 1,33 veces más costosos que aquellos con manejo médico (p?<?0,001), sin que ello afectara de manera significativa la duración de la estancia ni la tasa de letalidad. Conclusión: la trombólisis intravenosa en el ACVi implica un aumento significativo en los costos directos, pero reduce la carga de discapacidad en los pacientes tratados. Los costos se incrementan con la severidad del ACVi y la realización de algunos procedimientos adicionales.

  • Open Access

    Experiencia con el Biofire FilmArray® para meningitis/encefalitis infecciosa en una institución de alta complejidad en Bogotá, Colombia

    by Camilo A. Romero Hernández, Jessica L. Zuleta Motta, Neiry M. Zapa Pérez, Juan Diego Martínez Lemus

    Introduction. Infectious meningoencephalitis (IME) is a neurological emergency with a significant rate of morbidity and mortality. The Biofire FilmArray((R)) meningitis/encephalitis (FAME) panel for testing in cerebrospinal fluid (CSF) has proven to be a valuable tool for the aetiological diagnosis of IME, facilitating targeted antimicrobial therapy. The aim is to determine the impact of the FAME panel on antimicrobial therapeutic decisions in patients with suspected IME in the first 24 hours of clinical assessment. Patients and methods. This is a descriptive observational study that comments on the clinical manifestations, the neuroimaging and paraclinical findings, and the antibiotic therapy of patients with suspected IME. An analysis was performed to determine the impact of FAME on antimicrobial therapy in the first 24 hours of the clinical assessment of patients. Results. Altogether 44 patients were included. The average time required to obtain the result of the FAME panel for testing in CSF was nine hours, with 20.4% (9/44) of tests yielding positive results. Within 24 hours of clinical assessment, their outcome had an impact on antimicrobial treatment decisions in 75% (33/44) of cases. In patients with a high clinical suspicion of IME, the result of FAME made it possible to change the initial empirical therapy to a targeted therapy in 15% (3/20) of cases and to discontinue the initial empirical therapy in 35% (7/20) of the subjects. In patients with low clinical suspicion of IME, their result allowed 25% (6/24) to have their suspicion confirmed and they were started on targeted antibiotic therapy; in contrast, 70.8% (17/24) had their diagnosis ruled out and were not started on treatment. Conclusions. The result of the FAME panel for testing in CSF has a high impact on antimicrobial therapeutic decisions within 24 hours of clinical assessment. However, it must be interpreted with the clinical context, local epidemiology and other diagnostic studies.


  • Open Access

    Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings

    by Juan I. Guerrero, Luis A. Barragán, Juan D. Martínez, Juan P. Montoya, Alejandra Peña, Fidel E. Sobrino, Zulma Tovar-Spinoza, Kemel A. Ghotme

    Background: SARS-CoV-2 can affect the human brain and other neurological structures. An increasing number of publications report neurological manifestations in patients with COVID-19. However, no studies have comprehensively reviewed the clinical and paraclinical characteristics of the central and peripheral nervous system’s involvement in these patients. This study aimed to describe the features of the central and peripheral nervous system involvement by COVID-19 in terms of pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. Methods: We conducted a comprehensive systematic review of all the original studies reporting patients with neurological involvement by COVID-19, from December 2019 to June 2020, without language restriction. We excluded studies with animal subjects, studies not related to the nervous system, and opinion articles. Data analysis combined descriptive measures, frequency measures, central tendency measures, and dispersion measures for all studies reporting neurological conditions and abnormal ancillary tests in patients with confirmed COVID-19. Results: A total of 143 observational and descriptive studies reported central and peripheral nervous system involvement by COVID-19 in 10,723 patients. Fifty-one studies described pathophysiologic mechanisms of neurological involvement by COVID-19, 119 focused on clinical manifestations, 4 described neuropathology findings, 62 described neuroimaging findings, 28 electrophysiology findings, and 60 studies reported cerebrospinal fluid results. The reviewed studies reflect a significant prevalence of the nervous system’s involvement in patients with COVID-19, ranging from 22.5 to 36.4% among different studies, without mortality rates explicitly associated with neurological involvement by SARS-CoV-2. We thoroughly describe the clinical and paraclinical characteristics of neurological involvement in these patients. Conclusions: Our evidence synthesis led to a categorical analysis of the central and peripheral neurological involvement by COVID-19 and provided a comprehensive explanation of the reported pathophysiological mechanisms by which SARS-CoV-2 infection may cause neurological impairment. International collaborative efforts and exhaustive neurological registries will enhance the translational knowledge of COVID-19’s central and peripheral neurological involvement and generate therapeutic decision-making strategies. Registration: This review was registered in PROSPERO 2020 CRD42020193140 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020193140


  • Open Access

    Central and peripheral nervous system involvement by COVID-19: A systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings

    by Juan I. Guerrero, Luis A. Barragán, Juan D. Martínez, Juan P. Montoya, Alejandra Peña, Fidel E. Sobrino, Zulma Tovar-Spinoza, Kemel A. Ghotme

    Background: SARS-CoV-2 can affect the human brain and other neurological structures. An increasing number of publications report neurological manifestations in patients with COVID-19. However, no studies have comprehensively reviewed the clinical and paraclinical characteristics of the central and peripheral nervous system's involvement in these patients. This study aimed to describe the features of the central and peripheral nervous system involvement by COVID-19 in terms of pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings.Methods: We conducted a comprehensive systematic review of all the original studies reporting patients with neurological involvement by COVID-19, from December 2019 to June 2020, without language restriction. We excluded studies with animal subjects, studies not related to the nervous system, and opinion articles. Data analysis combined descriptive measures, frequency measures, central tendency measures, and dispersion measures for all studies reporting neurological conditions and abnormal ancillary tests in patients with confirmed COVID-19.Results: A total of 143 observational and descriptive studies reported central and peripheral nervous system involvement by COVID-19 in 10723 patients. Fifty-one studies described pathophysiologic mechanisms of neurological involvement by COVID-19, 119 focused on clinical manifestations, 4 described neuropathology findings, 62 described neuroimaging findings, 28 electrophysiology findings, and 60 studies reported cerebrospinal fluid results. The reviewed studies reflect a significant prevalence of the nervous system's involvement in patients with COVID-19, ranging from 22.5% to 36.4% among different studies, without mortality rates explicitly associated with neurological involvement by SARS-COV-2. We thoroughly describe the clinical and paraclinical characteristics of neurological involvement in these patients. Conclusions: Our evidence synthesis led to a categorical analysis of the central and peripheral involvement by COVID-19 and provided a comprehensive explanation of the reported pathophysiological mechanisms by which SARS-CoV-2 infection may cause neurological impairment. International collaborative efforts and exhaustive neurological registries will enhance the translational knowledge of COVID-19's CNS and PNS involvement and generate strategies for therapeutic decision-making.Registration: This review is registered in PROSPERO (CRD42020193140), July 24, 2020.